<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65386">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01824238</url>
  </required_header>
  <id_info>
    <org_study_id>0859-050</org_study_id>
    <secondary_id>132234</secondary_id>
    <nct_id>NCT01824238</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)</brief_title>
  <official_title>A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of anacetrapib (MK-0859) on low-density
      lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with
      heterozygous familial hypercholesterolemia when added to an existing statin lipid-modifying
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants who Experience at Least One Adverse Event (AE)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in High-density Lipoprotein-cholesterol (HDL-C)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Non-HDL-C</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Apolipoprotein B (Apo-B)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Lipoprotein(a) (Lp[a])</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Heterozygous Familial Hypercholesterolemia (HeFH)</condition>
  <arm_group>
    <arm_group_label>Anacetrapib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo tablet, orally, once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anacetrapib</intervention_name>
    <arm_group_label>Anacetrapib</arm_group_label>
    <other_name>MK-0859</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for anacetrapib</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  If female, cannot be of reproductive potential

          -  Diagnosed with heterozygous familial hypercholesterolemia

          -  Have been treated with an appropriate and

        stable dose of statinÂ± other lipid-lowering medication(s) for at least 6 weeks

        Exclusion Criteria:

          -  Previously participated in a study with a cholesteryl ester transfer protein (CETP)
             inhibitor

          -  Homozygous familial hypercholesterolemia

          -  Severe chronic heart failure

          -  Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary
             intervention (PCI), coronary artery by-pass graft (CABG), unstable angina, or stroke
             within 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
